Tyrosine kinase inhibitors in the treatment of systemic sclerosis: The difficulty in interpreting proof-of-concept studies

International Journal of Rheumatology

Volumn 2011, Issue , 2011, Pages

  Gordon, Jessica ^a   Spiera, Robert ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR;

ANEMIA; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DISEASE DURATION; DISEASE MODEL; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FIBROBLAST; FIBROSING ALVEOLITIS; FLUID RETENTION; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; INFECTION; LIVER TOXICITY; MORPHEA; MUSCLE CRAMP; MUSCLE SPASM; NAUSEA; NEPHROGENIC SYSTEMIC FIBROSIS; NEUTROPENIA; NONHUMAN; PANCREAS DISEASE; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SCLERODERMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SKIN TOXICITY; SYSTEMIC SCLEROSIS; THORAX PAIN; TREATMENT RESPONSE; VOMITING; WEAKNESS;

EID: 84855283317     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2011/842181     Document Type: Review

References (56)

1. Varga J., Abraham D., Systemic sclerosis: a prototypic multisystem fibrotic disorder Journal of Clinical Investigation 2007 117 3 557 567 (Pubitemid 46348510)
2. Varga J. A., Trojanowska M., Fibrosis in systemic sclerosis Rheumatic Disease Clinics of North America 2008 34 1 115 143 (Pubitemid 351329455)
3. Rosenbloom J., Castro S. V., Jimenez S. A., Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies Annals of Internal Medicine 2010 152 3 159 166
4. Gun D. D., Distler J. H. W., Riemekasten G., Distler O., Stimulatory autoantibodies to Platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology Arthritis and Rheumatism 2009 60 4 907 911
5. Distler J. H., Distler O., Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis Rheumatology 2008 47 v10 v11
6. Okimoto R. A., Van Etten R. A., Navigating the road toward optimal initial therapy for chronic myeloid leukemia Current Opinion in Hematology 2011 18 2 89 97
7. Cohen M. H., Williams G., Johnson J. R., Duan J., Gobburu J., Rahman A., Benson K., Leighton J., Kim S. K., Wood R., Rothmann M., Chen G., U K. M., Staten A. M., Pazdur R., Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia Clinical Cancer Research 2002 8 5 935 942 (Pubitemid 34520420)
8. Bueso-Ramos C. E., Cortes J., Talpaz M., O'Brien S., Giles F., Rios M. B., Medeiros L. J., Kantarjian H., Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia Cancer 2004 101 2 332 336 (Pubitemid 38890837)
9. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., Bochinski K., Hochhaus A., Griffin J. D., Hoelzer D., Albitar M., Dugan M., Cortes J., Alland L., Ottmann O. G., Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL New England Journal of Medicine 2006 354 24 2542 2551 (Pubitemid 43882350)
10. Talpaz M., Shah N. P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., Blackwood-Chirchir M. A., Iyer V., Chen T. T., Huang F., Decillis A. P., Sawyers C. L., Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias New England Journal of Medicine 2006 354 24 2531 2541 (Pubitemid 43882349)
11. Wei G., Rafiyath S., Liu D., First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib Journal of Hematology and Oncology 2010 3 47
12. Distler J. H. W., Jngel A., Huber L. C., Schulze-Horsel U., Zwerina J., Gay R. E., Michel B. A., Hauser T., Schett G., Gay S., Distler O., Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis Arthritis and Rheumatism 2007 56 1 311 322 (Pubitemid 46106205)
13. Akhmetshina A., Venalis P., Dees C., Busch N., Zwerina J., Schett G., Distler O., Distler J. H. W., Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis Arthritis and Rheumatism 2009 60 1 219 224
14. Wang S., Wilkes M. C., Leof E. B., Hirschberg R., Imatinib mesylate blocks a non-Smad TGF- pathway and reduces renal fibrogenesis in vivo FASEB Journal 2005 19 1 1 11 (Pubitemid 40069914)
15. Yoshiji H., Noguchi R., Kuriyama S., Ikenaka Y., Yoshii J., Yanase K., Namisaki T., Kitade M., Masaki T., Fukui H., Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats American Journal of PhysiologyGastrointestinal and Liver Physiology 2005 288 5 G907 G913
16. Daniels C. E., Wilkes M. C., Edens M., Kottom T. J., Murphy S. J., Limper A. H., Leof E. B., Imatinib mesylate inhibits the profibrogenic activity of TGF- and prevents bleomycin-mediated lung fibrosis Journal of Clinical Investigation 2004 114 9 1308 1316 (Pubitemid 40385302)
17. Sfikakis P. P., Gorgoulis V. G., Katsiari C. G., Evangelou K., Kostopoulos C., Black C. M., Imatinib for the treatment of refractory, diffuse systemic sclerosis Rheumatology 2008 47 5 735 737 (Pubitemid 351619226)
18. Van Daele P. L. A., Dik W. A., Thio H. B., Van Hal P. T. W., Van Laar J. A. M., Hooijkaas H., Van Hagen P. M., Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis and Rheumatism 2008 58 8 2549 2552
19. Distler J. H. W., Manger B., Spriewald B. M., Schett G., Distler O., Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease Arthritis and Rheumatism 2008 58 8 2538 2542
20. Chung L., Fiorentino D. F., BenBarak M. J., Adler A. S., Mariano M. M., Paniagua R. T., Milano A., Connolly M. K., Ratiner B. D., Wiskocil R. L., Whitfield M. L., Chang H. Y., Robinson W. H., Molecular framework for response to imatinib mesylate in systemic sclerosis Arthritis and Rheumatism 2009 60 2 584 591
21. Sabnani I., Zucker M. J., Rosenstein E. D., Baran D. A., Arroyo L. H., Tsang P., Zubair M., Rivera V., A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide Rheumatology 2009 48 1 49 52
22. Lesko L. J., Rowland M., Peck C. C., Blaschke T. F., Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans Journal of Clinical Pharmacology 2000 40 8 803 814
23. Abignano G., Buch M., Emery P., Del Galdo F., Biomarkers in the management of scleroderma: an update Current Rheumatology Reports 2011 13 1 4 12
24. Akhmetshina A., Venalis P., Dees C., Busch N., Zwerina J., Schett G., Distler O., Distler J. H. W., Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis Arthritis and Rheumatism 2009 60 1 219 224
25. Pannu J., Asano Y., Nakerakanti S., Smith E., Jablonska S., Blaszczyk M., Ten Dijke P., Trojanowska M., Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate Arthritis and Rheumatism 2008 58 8 2528 2537
26. Bhattacharyya S., Ishida W., Wu M., Wilkes M., Mori Y., Hinchcliff M., Leof E., Varga J., A non-Smad mechanism of fibroblast activation by transforming growth factor- via c-Abl and Egr-1: selective modulation by imatinib mesylate Oncogene 2009 28 10 1285 1297
27. Bujor A. M., Asano Y., Haines P., Lafyatis R., Trojanowska M., The c-abl tyrosine kinase controls PKC induced Fli1 phosphorylation in human dermal fibroblasts Arthritis Rheumatism 2011 63 6 1729 1737
28. Li Z., Jimenez S. A., Protein kinase C and the c-Abl kinase are required for transforming growth factor- induction of endothelial-mesenchymal transition in vitro Arthritis Rheumatism 2011 63 8 2473 2483
29. Maurer B., Stanczyk J., Jngel A., Akhmetshina A., Trenkmann M., Brock M., Kowal-Bielecka O., Gay R. E., Michel B. A., Distler J. H. W., Gay S., Distler O., MicroRNA-29, a key regulator of collagen expression in systemic sclerosis Arthritis and Rheumatism 2010 62 6 1733 1743
30. Kay J., High W. A., Imatinib mesylate treatment of nephrogenic systemic fibrosis Arthritis and Rheumatism 2008 58 8 2543 2548
31. Olivieri A., Locatelli F., Zecca M., Sanna A., Cimminiello M., Raimondi R., Gini G., Mordini N., Balduzzi A., Leoni P., Gabrielli A., Bacigalupo A., Imatinib for refractory chronic graft-versus-host disease with fibrotic features Blood 2009 114 3 709 718
32. Magro L., Mohty M., Catteau B., Coiteux V., Chevallier P., Terriou L., Jouet J. P., Yakoub-Agha I., Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease Blood 2009 114 3 719 722
33. Moinzadeh P., Krieg T., Hunzelmann N., Imatinib treatment of generalized localized scleroderma (morphea) Journal of the American Academy of Dermatology 2010 63 5 e102 e104
34. Daniels C. E., Lasky J. A., Limper A. H., Mieras K., Gabor E., Schroeder D. R., Chapman J., Nathan S., Selman M., Alex C., Lee A., Ginns L., De Andrade J., Noth I., Glassberg M., Lieber J., Lancaster L., Nobel P., Pascoe S., Duffy J. A., Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results American Journal of Respiratory and Critical Care Medicine 2010 181 6 604 610
35. Wei G., Rafiyath S., Liu D., First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib Journal of Hematology and Oncology 2010 3 47
36. Kerkel R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S., Clubb F. J., Rosenzweig A., Salomon R. N., Van Etten R. A., Alroy J., Durand J. B., Force T., Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nature Medicine 2006 12 8 908 916 (Pubitemid 44175142)
37. Atallah E., Durand J. B., Kantarjian H., Cortes J., Congestive heart failure is a rare event in patients receiving imatinib therapy Blood 2007 110 4 1233 1237 (Pubitemid 47281421)
38. Breccia M., Cannella L., Frustaci A., Stefanizzi C., Levi A., Alimena G., Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: a single institution experience Leukemia Research 2008 32 5 835 836 (Pubitemid 351323927)
39. Novartis, Tasigna (nilotinib) US prescribing information. Revised 2010
40. Gordon J. K., Magid S. K., Maki R. G., Fleisher M., Berman E., Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec) Leukemia Research 2010 34 6 827 829
41. Winkler E. A., Bell R. D., Zlokovic B. V., Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling Molecular Neurodegeneration 2010 5 1, article 32
42. Barst R. J., PDGF signaling in pulmonary artery hypertension The Journal of Clinical Investigation 2005 115 2691 2694 (Pubitemid 41434394)
43. Hatano M., Yao A., Shiga T., Kinugawa K., Hirata Y., Nagai R., Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension International Heart Journal 2010 51 4 272 276
44. Gordon J., Spiera R., Imatinib and the treatment of fibrosis: recent trials and tribulations Current Rheumatology Reports 2011 13 1 51 58
45. http://www.clinicaltrials.gov/ct2/show/study/NCT00764309?term= dasatinib+in+sclerodermarank=1, 2011
46. Spiera R. F., Gordon J. K., Mersten J. N., Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial Annals of Rheumatic Diseases 2011 70 6 1003 1009
47. White B., Bauer E. A., Goldsmith L. A., Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis Arthritis Rheumatism 1995 38 3 351 360
48. Pope J., McBain D., Petrlich L., Imatinib in active diffuse systemic sclerosis: a single site trial. Arthritis and Rheumatism. In press
49. Mendoza F. A., Jimenez S. A., Tyrosine kinase inhibitor therapy for systemic sclerosis: quo vadis? Arthritis and Rheumatism. In press
50. Van Hest R. M., Schnog J. B., Van't Veer M. B., Cornelissen J. J., Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinib American Journal of Hematology 2008 83 9 757 758
51. Khanna D., Saggar R., Mayes M. D., Open-label pilot trial of imatinib mesylate (Gleevec) in the treatment of systemic sclerosis- associated active interstitial lung disease (SSc-ILD). Arthritis and Rheumatism. In press
52. Tashkin D. P., Elashoff R., Clements P. J., Goldin J., Roth M. D., Furst D. E., Arriola E., Silver R., Strange C., Bolster M., Seibold J. R., Riley D. J., Hsu V. M., Varga J., Schraufnagel D. E., Theodore A., Simms R., Wise R., Wigley F., White B., Steen V., Read C., Mayes M., Parsley E., Mubarak K., Connolly M. K., Golden J., Olman M., Fessler B., Rothfield N., Metersky M., Cyclophosphamide versus placebo in scleroderma lung disease The New England Journal of Medicine 2006 354 25 2655 2666
53. Chung L., Ruiz P., Wood T., Evaluation of an imatinib response gene signature in patients with systemic sclerosis [abstract] Proceedings of the American College of Rheumatology Annual Scientific Meeting November 2010 Atlanta, Ga, USA
54. Chung L., Fiorentino D. F., BenBarak M. J., Adler A. S., Mariano M. M., Paniagua R. T., Milano A., Connolly M. K., Ratiner B. D., Wiskocil R. L., Whitfield M. L., Chang H. Y., Robinson W. H., Molecular framework for response to imatinib mesylate in systemic sclerosis Arthritis and Rheumatism 2009 60 2 584 591
55. Denton C. P., Nihtyanova S. I., Varga J., Comparative analysis of change in modified Rodnan skin score in patients with diffuse systemic sclerosis receiving imatinib mesylate suggests similar disease course to matched patients receiving standard therapy [abstract] Proceedings of the American College of Rheumatology Annual Scientific Meeting November 2010 Atlanta, Ga, USA
56. Amjadi S., Maranian P., Furst D. E., Investigators of the D-Penicillamine, Human Recombinant Relaxin, and Oral Bovine Type I Collagen Clinical TrialsCourse of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials Arthritis Rheumatism 2009 60 8 2490 2498